Shawn Williams

US Patent:

20040018560, Jan 29, 2004

Filed:

Apr 17, 2003

Appl. No.:

10/418007

Inventors:

Randy Bledsoe - Durham NC, US
Ann Miller - Wilmington NC, US
John Moore - Durham NC, US
Linda Moore - Durham NC, US
Shawn Williams - Durham NC, US
George Wisely - Durham NC, US

International Classification:

G01N033/53
G06F019/00
G01N033/48
G01N033/50
C07K014/705

US Classification:

435/007100, 530/350000, 702/019000

Abstract:

Solved three-dimensional crystal structures of a human LXR ligand binding domain polypeptide in complex with one or more of a ligand and a coactivator polypeptide is disclosed. Contact points between the LXR and the ligands are also disclosed. Additionally, methods of designing modulators of the biological activity of LXR, and other LXR ligand binding domain polypeptides, are also disclosed.

US Patent:

20050131209, Jun 16, 2005

Filed:

Jan 31, 2002

Appl. No.:

10/470958

Inventors:

Roderick Davis - Durham NC, US
Robert Johnson - Durham NC, US
Aaren Miller - Durham NC, US
James Way - Durham NC, US
Shawn Williams - Durham NC, US
Timothy Willson - Durham NC, US
George Wisely - Durham NC, US
Ann Kontz - Wilmington NC, US

International Classification:

C07K014/72
G06F019/00
G01N033/48
G01N033/50

US Classification:

530350000, 702019000

Abstract:

A solved three-dimensional crystal structure of an HNF4g ligand binding domain polypeptide is disclosed, along with a crystal form of the HNF4g ligand binding domain. Methods of designing modulators of the biological activity of HNF4g, and other HNF4 ligand binding domain polypeptides are also disclosed.

US Patent:

20070219348, Sep 20, 2007

Filed:

Mar 16, 2006

Appl. No.:

11/377502

Inventors:

Christopher Apolito - Durham NC, US
Randy Bledsoe - Durham NC, US
Millard Lambert - Durham NC, US
Kevin Madauss - Durham NC, US
Thomas Stanley - Durham NC, US
Eugene Stewart - Durham NC, US
Shawn Williams - Durham NC, US

International Classification:

C07K 14/715
G06F 19/00

US Classification:

530350000, 702019000

Abstract:

An isolated mineralocorticoid receptor (MR) polypeptide, or functional portion thereof, having one or more mutations that alter the solubility or crystal-forming properties and confer the ability to generate soluble protein complexes with the MR and ligands that only weakly bind the native polypeptide, and a polynucleotide encoding it are disclosed. Representative mutations are C808S and S810L substitutions. Expression of the MR polypeptide in is also provided. A solved three-dimensional crystal structure of an MR ligand binding domain polypeptide is also disclosed, along with a crystalline form of the MR ligand binding domain polypeptide. Methods of modeling one or more molecular interactions of a native NR with a ligand having low affinity for the native NR utilizing a mutated MR, designing modulators of the biological activity of MR and other nuclear receptor, steroid receptor and glucocorticoid receptor polypeptides and nuclear receptor, steroid receptor and glucocorticoid receptor ligand binding domain polypeptides are also disclosed.